ID   DYR1A_HUMAN             Reviewed;         763 AA.
AC   Q13627; O60769; Q92582; Q92810; Q9UNM5;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   15-JUL-1998, sequence version 2.
DT   12-OCT-2022, entry version 220.
DE   RecName: Full=Dual specificity tyrosine-phosphorylation-regulated kinase 1A;
DE            EC=2.7.11.23 {ECO:0000269|PubMed:25620562};
DE            EC=2.7.12.1 {ECO:0000269|PubMed:20981014, ECO:0000269|PubMed:22998443, ECO:0000269|PubMed:23665168, ECO:0000269|PubMed:24239188, ECO:0000269|PubMed:30773093};
DE   AltName: Full=Dual specificity YAK1-related kinase;
DE   AltName: Full=HP86;
DE   AltName: Full=Protein kinase minibrain homolog {ECO:0000303|PubMed:8872470, ECO:0000303|PubMed:8975710};
DE            Short=MNBH;
DE            Short=hMNB;
GN   Name=DYRK1A {ECO:0000303|PubMed:25620562, ECO:0000312|HGNC:HGNC:3091};
GN   Synonyms=DYRK, MNB {ECO:0000303|PubMed:8872470}, MNBH;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM LONG), VARIANT PRO-679, AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Fetal brain;
RX   PubMed=8975710; DOI=10.1006/geno.1996.0636;
RA   Song W.J., Sternberg L.R., Kasten-Sportes C., van Keuren M.L., Chung S.H.,
RA   Slack A.C., Miller D.E., Glover T.W., Chiang P.W., Lou L., Kurnit D.W.;
RT   "Isolation of human and murine homologues of the Drosophila minibrain gene:
RT   human homologue maps to 21q22.2 in the Down syndrome 'critical region'.";
RL   Genomics 38:331-339(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM LONG), TISSUE SPECIFICITY, AND POSSIBLE
RP   INVOLVEMENT IN DOWN SYNDROME.
RX   PubMed=8872470; DOI=10.1093/hmg/5.9.1305;
RA   Guimera J., Casas C., Pucharcos C., Solans A., Domenech A., Planas A.M.,
RA   Ashley J., Lovett M., Estivill X., Pritchard M.A.;
RT   "A human homologue of Drosophila minibrain (MNB) is expressed in the
RT   neuronal regions affected in Down syndrome and maps to the critical
RT   region.";
RL   Hum. Mol. Genet. 5:1305-1310(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, TISSUE SPECIFICITY, AND
RP   DEVELOPMENTAL STAGE.
RC   TISSUE=Fetal brain;
RX   PubMed=8769099; DOI=10.1006/bbrc.1996.1135;
RA   Shindoh N., Kudoh J., Maeda H., Yamaki A., Minoshima S., Shimizu Y.,
RA   Shimizu N.;
RT   "Cloning of a human homolog of the Drosophila minibrain/rat Dyrk gene from
RT   'the Down syndrome critical region' of chromosome 21.";
RL   Biochem. Biophys. Res. Commun. 225:92-99(1996).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Promyelocytic leukemia;
RX   PubMed=9037601; DOI=10.1101/gr.7.1.47;
RA   Ohira M., Seki N., Nagase T., Suzuki E., Nomura N., Ohara O., Hattori M.,
RA   Sakaki Y., Eki T., Murakami Y., Saito T., Ichikawa H., Ohki M.;
RT   "Gene identification in 1.6-Mb region of the Down syndrome region on
RT   chromosome 21.";
RL   Genome Res. 7:47-58(1997).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4), TISSUE SPECIFICITY, POSSIBLE
RP   INVOLVEMENT IN DOWN SYNDROME, VARIANTS PHE-415 AND HIS-681, AND ALTERNATIVE
RP   SPLICING.
RX   PubMed=10329007; DOI=10.1006/geno.1999.5775;
RA   Guimera J., Casas C., Estivill X., Pritchard M.A.;
RT   "Human minibrain homologue (MNBH/DYRK1): characterization, alternative
RT   splicing, differential tissue expression, and overexpression in Down
RT   syndrome.";
RL   Genomics 57:407-418(1999).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 234-380.
RC   TISSUE=Fetal brain;
RX   PubMed=9503011; DOI=10.1006/geno.1997.5146;
RA   Dahmane N., Ait-Ghezala G., Gosset P., Chamoun Z., Dufresne-Zacharia M.-C.,
RA   Lopes C., Rabatel N., Gassanova-Maugenre S., Chettouh Z., Abramowski V.,
RA   Fayet E., Yaspo M.-L., Korn B., Blouin J.-L., Lehrach H., Poustka A.,
RA   Antonarakis S.E., Sinet P.-M., Creau N., Delabar J.-M.;
RT   "Transcriptional map of the 2.5-Mb CBR-ERG region of chromosome 21 involved
RT   in Down syndrome.";
RL   Genomics 48:12-23(1998).
RN   [7]
RP   INTERACTION WITH RANBP9, FUNCTION, AND ACTIVITY REGULATION.
RX   PubMed=14500717; DOI=10.1074/jbc.m307556200;
RA   Zou Y., Lim S., Lee K., Deng X., Friedman E.;
RT   "Serine/threonine kinase Mirk/Dyrk1B is an inhibitor of epithelial cell
RT   migration and is negatively regulated by the Met adaptor Ran-binding
RT   protein M.";
RL   J. Biol. Chem. 278:49573-49581(2003).
RN   [8]
RP   INTERACTION WITH WDR68.
RX   PubMed=14593110; DOI=10.1074/jbc.m301769200;
RA   Skurat A.V., Dietrich A.D.;
RT   "Phosphorylation of Ser640 in muscle glycogen synthase by DYRK family
RT   protein kinases.";
RL   J. Biol. Chem. 279:2490-2498(2004).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=15592455; DOI=10.1038/nbt1046;
RA   Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H.,
RA   Zha X.-M., Polakiewicz R.D., Comb M.J.;
RT   "Immunoaffinity profiling of tyrosine phosphorylation in cancer cells.";
RL   Nat. Biotechnol. 23:94-101(2005).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-748 AND SER-758, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [11]
RP   POLY-HISTIDINE REPEATS.
RX   PubMed=19266028; DOI=10.1371/journal.pgen.1000397;
RA   Salichs E., Ledda A., Mularoni L., Alba M.M., de la Luna S.;
RT   "Genome-wide analysis of histidine repeats reveals their role in the
RT   localization of human proteins to the nuclear speckles compartment.";
RL   PLoS Genet. 5:E1000397-E1000397(2009).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-145, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [13]
RP   SUBCELLULAR LOCATION.
RX   PubMed=20167603; DOI=10.1074/jbc.m110.102574;
RA   Guo X., Williams J.G., Schug T.T., Li X.;
RT   "DYRK1A and DYRK3 promote cell survival through phosphorylation and
RT   activation of SIRT1.";
RL   J. Biol. Chem. 285:13223-13232(2010).
RN   [14]
RP   INVOLVEMENT IN MRD7.
RX   PubMed=21294719; DOI=10.1111/j.1399-0004.2010.01544.x;
RA   van Bon B.W., Hoischen A., Hehir-Kwa J., de Brouwer A.P., Ruivenkamp C.,
RA   Gijsbers A.C., Marcelis C.L., de Leeuw N., Veltman J.A., Brunner H.G.,
RA   de Vries B.B.;
RT   "Intragenic deletion in DYRK1A leads to mental retardation and primary
RT   microcephaly.";
RL   Clin. Genet. 79:296-299(2011).
RN   [15]
RP   FUNCTION, AND SUBSTRATE SPECIFICITY.
RX   PubMed=21127067; DOI=10.1074/jbc.m110.157909;
RA   Papadopoulos C., Arato K., Lilienthal E., Zerweck J., Schutkowski M.,
RA   Chatain N., Muller-Newen G., Becker W., de la Luna S.;
RT   "Splice variants of the dual specificity tyrosine phosphorylation-regulated
RT   kinase 4 (DYRK4) differ in their subcellular localization and catalytic
RT   activity.";
RL   J. Biol. Chem. 286:5494-5505(2011).
RN   [16]
RP   INVOLVEMENT IN MRD7.
RX   PubMed=23160955; DOI=10.1126/science.1227764;
RA   O'Roak B.J., Vives L., Fu W., Egertson J.D., Stanaway I.B., Phelps I.G.,
RA   Carvill G., Kumar A., Lee C., Ankenman K., Munson J., Hiatt J.B.,
RA   Turner E.H., Levy R., O'Day D.R., Krumm N., Coe B.P., Martin B.K.,
RA   Borenstein E., Nickerson D.A., Mefford H.C., Doherty D., Akey J.M.,
RA   Bernier R., Eichler E.E., Shendure J.;
RT   "Multiplex targeted sequencing identifies recurrently mutated genes in
RT   autism spectrum disorders.";
RL   Science 338:1619-1622(2012).
RN   [17]
RP   SUBCELLULAR LOCATION.
RX   PubMed=23415227; DOI=10.1016/j.cell.2013.01.033;
RA   Wippich F., Bodenmiller B., Trajkovska M.G., Wanka S., Aebersold R.,
RA   Pelkmans L.;
RT   "Dual specificity kinase DYRK3 couples stress granule
RT   condensation/dissolution to mTORC1 signaling.";
RL   Cell 152:791-805(2013).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-14 AND TYR-145, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [19]
RP   INTERACTION WITH HADV5 E1A (MICROBIAL INFECTION).
RX   PubMed=23864635; DOI=10.1128/jvi.00786-13;
RA   Cohen M.J., Yousef A.F., Massimi P., Fonseca G.J., Todorovic B., Pelka P.,
RA   Turnell A.S., Banks L., Mymryk J.S.;
RT   "Dissection of the C-terminal region of E1A redefines the roles of CtBP and
RT   other cellular targets in oncogenic transformation.";
RL   J. Virol. 87:10348-10355(2013).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-529, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [21]
RP   FUNCTION.
RX   PubMed=31024071; DOI=10.1038/s41598-019-42990-5;
RA   Guard S.E., Poss Z.C., Ebmeier C.C., Pagratis M., Simpson H., Taatjes D.J.,
RA   Old W.M.;
RT   "The nuclear interactome of DYRK1A reveals a functional role in DNA damage
RT   repair.";
RL   Sci. Rep. 9:6539-6539(2019).
RN   [22]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=30773093; DOI=10.1080/15384101.2019.1577525;
RA   Menon V.R., Ananthapadmanabhan V., Swanson S., Saini S., Sesay F.,
RA   Yakovlev V., Florens L., DeCaprio J.A., Washburn M.P., Dozmorov M.,
RA   Litovchick L.;
RT   "DYRK1A regulates the recruitment of 53BP1 to the sites of DNA damage in
RT   part through interaction with RNF169.";
RL   Cell Cycle 18:531-551(2019).
RN   [23]
RP   X-RAY CRYSTALLOGRAPHY (2.60 ANGSTROMS) OF 126-490 IN COMPLEXES WITH THE
RP   SYNTHETIC INHIBITORS HARMINE AND INDY, CATALYTIC ACTIVITY, AND FUNCTION.
RX   PubMed=20981014; DOI=10.1038/ncomms1090;
RA   Ogawa Y., Nonaka Y., Goto T., Ohnishi E., Hiramatsu T., Kii I., Yoshida M.,
RA   Ikura T., Onogi H., Shibuya H., Hosoya T., Ito N., Hagiwara M.;
RT   "Development of a novel selective inhibitor of the Down syndrome-related
RT   kinase Dyrk1A.";
RL   Nat. Commun. 1:86-86(2010).
RN   [24]
RP   X-RAY CRYSTALLOGRAPHY (3.15 ANGSTROMS) OF 128-485, CATALYTIC ACTIVITY, AND
RP   ACTIVITY REGULATION.
RX   PubMed=22998443; DOI=10.1021/jm301034u;
RA   Tahtouh T., Elkins J.M., Filippakopoulos P., Soundararajan M., Burgy G.,
RA   Durieu E., Cochet C., Schmid R.S., Lo D.C., Delhommel F., Oberholzer A.E.,
RA   Pearl L.H., Carreaux F., Bazureau J.P., Knapp S., Meijer L.;
RT   "Selectivity, cocrystal structures, and neuroprotective properties of
RT   leucettines, a family of protein kinase inhibitors derived from the marine
RT   sponge alkaloid leucettamine B.";
RL   J. Med. Chem. 55:9312-9330(2012).
RN   [25]
RP   X-RAY CRYSTALLOGRAPHY (2.35 ANGSTROMS) OF 127-485 IN COMPLEX WITH SYNTHETIC
RP   INHIBITOR, AND CATALYTIC ACTIVITY.
RX   PubMed=24239188; DOI=10.1016/j.bmcl.2013.10.055;
RA   Anderson K., Chen Y., Chen Z., Dominique R., Glenn K., He Y., Janson C.,
RA   Luk K.C., Lukacs C., Polonskaia A., Qiao Q., Railkar A., Rossman P.,
RA   Sun H., Xiang Q., Vilenchik M., Wovkulich P., Zhang X.;
RT   "Pyrido[2,3-d]pyrimidines: discovery and preliminary SAR of a novel series
RT   of DYRK1B and DYRK1A inhibitors.";
RL   Bioorg. Med. Chem. Lett. 23:6610-6615(2013).
RN   [26]
RP   FUNCTION, CATALYTIC ACTIVITY, SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   LYS-188.
RX   PubMed=25620562; DOI=10.1016/j.molcel.2014.12.026;
RA   Di Vona C., Bezdan D., Islam A.B., Salichs E., Lopez-Bigas N., Ossowski S.,
RA   de la Luna S.;
RT   "Chromatin-wide profiling of DYRK1A reveals a role as a gene-specific RNA
RT   polymerase II CTD kinase.";
RL   Mol. Cell 57:506-520(2015).
RN   [27]
RP   FUNCTION, AND DOMAIN.
RX   PubMed=29849146; DOI=10.1038/s41586-018-0174-3;
RA   Lu H., Yu D., Hansen A.S., Ganguly S., Liu R., Heckert A., Darzacq X.,
RA   Zhou Q.;
RT   "Phase-separation mechanism for C-terminal hyperphosphorylation of RNA
RT   polymerase II.";
RL   Nature 558:318-323(2018).
RN   [28]
RP   X-RAY CRYSTALLOGRAPHY (2.40 ANGSTROMS) OF 127-485 IN COMPLEXES WITH PEPTIDE
RP   SUBSTRATE AND INHIBITOR DJM2005, CATALYTIC ACTIVITY, FUNCTION,
RP   AUTOPHOSPHORYLATION, MUTAGENESIS OF LYS-188 AND TYR-321, PHOSPHORYLATION AT
RP   TYR-111; TYR-140; TYR-159; TYR-177; SER-310; TYR-319; TYR-321; THR-402 AND
RP   TYR-449, ACTIVE SITE, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=23665168; DOI=10.1016/j.str.2013.03.012;
RA   Soundararajan M., Roos A.K., Savitsky P., Filippakopoulos P.,
RA   Kettenbach A.N., Olsen J.V., Gerber S.A., Eswaran J., Knapp S.,
RA   Elkins J.M.;
RT   "Structures of Down syndrome kinases, DYRKs, reveal mechanisms of kinase
RT   activation and substrate recognition.";
RL   Structure 21:986-996(2013).
RN   [29]
RP   VARIANT [LARGE SCALE ANALYSIS] PRO-679.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Dual-specificity kinase which possesses both serine/threonine
CC       and tyrosine kinase activities (PubMed:21127067, PubMed:8769099,
CC       PubMed:30773093, PubMed:20981014, PubMed:23665168). Exhibits a
CC       substrate preference for proline at position P+1 and arginine at
CC       position P-3 (PubMed:23665168). Plays an important role in double-
CC       strand breaks (DSBs) repair following DNA damage (PubMed:31024071).
CC       Mechanistically, phosphorylates RNF169 and increases its ability to
CC       block accumulation of TP53BP1 at the DSB sites thereby promoting
CC       homologous recombination repair (HRR) (PubMed:30773093). Also acts as a
CC       positive regulator of transcription by acting as a CTD kinase that
CC       mediates phosphorylation of the CTD (C-terminal domain) of the large
CC       subunit of RNA polymerase II (RNAP II) POLR2A (PubMed:25620562,
CC       PubMed:29849146). May play a role in a signaling pathway regulating
CC       nuclear functions of cell proliferation (PubMed:14500717). Modulates
CC       alternative splicing by phosphorylating the splice factor SRSF6 (By
CC       similarity). Has pro-survival function and negatively regulates the
CC       apoptotic process (By similarity). Promotes cell survival upon
CC       genotoxic stress through phosphorylation of SIRT1 (By similarity). This
CC       in turn inhibits p53/TP53 activity and apoptosis (By similarity).
CC       Phosphorylates SEPTIN4, SEPTIN5 and SF3B1 at 'Thr-434' (By similarity).
CC       {ECO:0000250|UniProtKB:Q61214, ECO:0000250|UniProtKB:Q63470,
CC       ECO:0000269|PubMed:14500717, ECO:0000269|PubMed:20981014,
CC       ECO:0000269|PubMed:21127067, ECO:0000269|PubMed:23665168,
CC       ECO:0000269|PubMed:25620562, ECO:0000269|PubMed:29849146,
CC       ECO:0000269|PubMed:30773093, ECO:0000269|PubMed:31024071,
CC       ECO:0000269|PubMed:8769099}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.12.1;
CC         Evidence={ECO:0000269|PubMed:20981014, ECO:0000269|PubMed:22998443,
CC         ECO:0000269|PubMed:23665168, ECO:0000269|PubMed:24239188,
CC         ECO:0000269|PubMed:30773093};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.12.1; Evidence={ECO:0000269|PubMed:20981014,
CC         ECO:0000269|PubMed:22998443, ECO:0000269|PubMed:23665168,
CC         ECO:0000269|PubMed:24239188};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl-
CC         [protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=2.7.12.1;
CC         Evidence={ECO:0000269|PubMed:20981014, ECO:0000269|PubMed:22998443,
CC         ECO:0000269|PubMed:23665168, ECO:0000269|PubMed:24239188};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=[DNA-directed RNA polymerase] + ATP = ADP + H(+) + phospho-
CC         [DNA-directed RNA polymerase]; Xref=Rhea:RHEA:10216, Rhea:RHEA-
CC         COMP:11321, Rhea:RHEA-COMP:11322, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:43176, ChEBI:CHEBI:68546,
CC         ChEBI:CHEBI:456216; EC=2.7.11.23;
CC         Evidence={ECO:0000269|PubMed:25620562};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:10217;
CC         Evidence={ECO:0000269|PubMed:25620562};
CC   -!- ACTIVITY REGULATION: Inhibited by RANBP9 (PubMed:14500717). Inhibited
CC       by harmine, leucettamine B and leucettine L41 (PubMed:22998443).
CC       {ECO:0000269|PubMed:14500717, ECO:0000269|PubMed:22998443}.
CC   -!- SUBUNIT: Interacts RAD54L2/ARIP4 (By similarity). Interacts with CRY2
CC       (By similarity). Interacts with RANBP9 (PubMed:14500717). Interacts
CC       with WDR68 (PubMed:14593110). Interacts with SIRT1 (By similarity).
CC       {ECO:0000250|UniProtKB:Q61214, ECO:0000269|PubMed:14500717,
CC       ECO:0000269|PubMed:14593110}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with human adenovirus 5 E1A
CC       protein (PubMed:23864635). {ECO:0000269|PubMed:23864635}.
CC   -!- INTERACTION:
CC       Q13627; P61962: DCAF7; NbExp=8; IntAct=EBI-1053596, EBI-359808;
CC       Q13627; Q5T749: KPRP; NbExp=3; IntAct=EBI-1053596, EBI-10981970;
CC       Q13627; Q9BRK4: LZTS2; NbExp=4; IntAct=EBI-1053596, EBI-741037;
CC       Q13627; P06400: RB1; NbExp=4; IntAct=EBI-1053596, EBI-491274;
CC       Q13627; P28749: RBL1; NbExp=4; IntAct=EBI-1053596, EBI-971402;
CC       Q13627; Q12815: TROAP; NbExp=4; IntAct=EBI-1053596, EBI-2349743;
CC       Q13627-1; Q13627-1: DYRK1A; NbExp=2; IntAct=EBI-1053617, EBI-1053617;
CC       Q13627-2; P31946: YWHAB; NbExp=3; IntAct=EBI-1053621, EBI-359815;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:20167603,
CC       ECO:0000269|PubMed:23415227, ECO:0000269|PubMed:25620562}. Nucleus
CC       speckle {ECO:0000250|UniProtKB:Q61214}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC         Comment=Additional isoforms seem to exist.;
CC       Name=Long;
CC         IsoId=Q13627-1; Sequence=Displayed;
CC       Name=1;
CC         IsoId=Q13627-2; Sequence=VSP_004917;
CC       Name=2;
CC         IsoId=Q13627-3; Sequence=VSP_004918, VSP_004919;
CC       Name=3;
CC         IsoId=Q13627-4; Sequence=VSP_004920, VSP_004921;
CC       Name=4;
CC         IsoId=Q13627-5; Sequence=VSP_004922, VSP_004923;
CC   -!- TISSUE SPECIFICITY: Ubiquitous. Highest levels in skeletal muscle,
CC       testis, fetal lung and fetal kidney. {ECO:0000269|PubMed:10329007,
CC       ECO:0000269|PubMed:8769099, ECO:0000269|PubMed:8872470,
CC       ECO:0000269|PubMed:8975710}.
CC   -!- DEVELOPMENTAL STAGE: Expressed in the developing central nervous
CC       system. Overexpressed 1.5-fold in fetal Down syndrome brain.
CC       {ECO:0000269|PubMed:8769099}.
CC   -!- DOMAIN: The polyhistidine repeats act as targeting signals to nuclear
CC       speckles. {ECO:0000269|PubMed:19266028}.
CC   -!- DOMAIN: The histidine-rich domain (HRD) region is intrinsically
CC       disordered and promotes the formation of phase-separated liquid
CC       droplets that enhance its ability to phosphorylate the CTD (C-terminal
CC       domain) of the large subunit of RNA polymerase II (RNA Pol II).
CC       {ECO:0000269|PubMed:29849146}.
CC   -!- PTM: Autophosphorylated on numerous tyrosine residues. Can also
CC       autophosphorylate on serine and threonine residues (in vitro).
CC       {ECO:0000269|PubMed:23665168}.
CC   -!- DISEASE: Intellectual developmental disorder, autosomal dominant 7
CC       (MRD7) [MIM:614104]: A disease characterized by primary microcephaly,
CC       severe intellectual disability without speech, anxious autistic
CC       behavior, and dysmorphic features, including bitemporal narrowing,
CC       deep-set eyes, large simple ears, and a pointed nasal tip. Intellectual
CC       disability is characterized by significantly below average general
CC       intellectual functioning associated with impairments in adaptive
CC       behavior and manifested during the developmental period.
CC       {ECO:0000269|PubMed:21294719, ECO:0000269|PubMed:23160955}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CMGC Ser/Thr
CC       protein kinase family. MNB/DYRK subfamily. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/DYRK1AID43234ch21q22.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U58496; AAC50939.1; -; mRNA.
DR   EMBL; U52373; AAB18639.1; -; mRNA.
DR   EMBL; D85759; BAA12866.1; -; mRNA.
DR   EMBL; D86550; BAA13110.1; -; mRNA.
DR   EMBL; AF108830; AAD31169.1; -; mRNA.
DR   EMBL; AJ001870; CAA05059.1; -; mRNA.
DR   CCDS; CCDS13653.1; -. [Q13627-2]
DR   CCDS; CCDS13654.1; -. [Q13627-3]
DR   CCDS; CCDS42925.1; -. [Q13627-1]
DR   CCDS; CCDS42926.1; -. [Q13627-5]
DR   PIR; JC4898; JC4898.
DR   RefSeq; NP_001334650.1; NM_001347721.1. [Q13627-2]
DR   RefSeq; NP_001334651.1; NM_001347722.1. [Q13627-2]
DR   RefSeq; NP_001387.2; NM_001396.4. [Q13627-1]
DR   RefSeq; NP_567824.1; NM_101395.2. [Q13627-5]
DR   RefSeq; NP_569120.1; NM_130436.2. [Q13627-2]
DR   RefSeq; NP_569122.1; NM_130438.2. [Q13627-3]
DR   RefSeq; XP_006724039.1; XM_006723976.3. [Q13627-1]
DR   RefSeq; XP_006724040.1; XM_006723977.3. [Q13627-1]
DR   RefSeq; XP_006724041.1; XM_006723978.3. [Q13627-1]
DR   RefSeq; XP_011527785.1; XM_011529483.2. [Q13627-1]
DR   RefSeq; XP_016883773.1; XM_017028284.1. [Q13627-2]
DR   PDB; 2VX3; X-ray; 2.40 A; A/B/C/D=127-485.
DR   PDB; 2WO6; X-ray; 2.50 A; A/B=127-485.
DR   PDB; 3ANQ; X-ray; 2.60 A; A/B/C/D=126-490.
DR   PDB; 3ANR; X-ray; 2.60 A; A/B/C/D=126-490.
DR   PDB; 4AZE; X-ray; 3.15 A; A/B/C=128-485.
DR   PDB; 4MQ1; X-ray; 2.35 A; A/B/C/D=127-485.
DR   PDB; 4MQ2; X-ray; 2.80 A; A/B/C/D=127-485.
DR   PDB; 4NCT; X-ray; 2.60 A; A/B/C/D=126-490.
DR   PDB; 4YLJ; X-ray; 2.58 A; A/B/C/D=127-485.
DR   PDB; 4YLK; X-ray; 1.40 A; A=127-485.
DR   PDB; 4YLL; X-ray; 1.40 A; A=127-485.
DR   PDB; 4YU2; X-ray; 2.90 A; A/B/C/D=127-485.
DR   PDB; 5A3X; X-ray; 2.26 A; A/B/C/D=126-490.
DR   PDB; 5A4E; X-ray; 2.68 A; A/B/C/D=126-490.
DR   PDB; 5A4L; X-ray; 2.73 A; A/B/C/D=126-490.
DR   PDB; 5A4Q; X-ray; 2.37 A; A/B/C/D=126-490.
DR   PDB; 5A4T; X-ray; 2.15 A; A/B/C/D=126-490.
DR   PDB; 5A54; X-ray; 2.63 A; A/B/C/D=126-490.
DR   PDB; 5AIK; X-ray; 2.70 A; A/B/C/D=128-485.
DR   PDB; 6A1F; X-ray; 1.50 A; A=127-483.
DR   PDB; 6A1G; X-ray; 2.15 A; A/B=127-483.
DR   PDB; 6EIF; X-ray; 2.22 A; A/B/C/D=126-490.
DR   PDB; 6EIJ; X-ray; 2.42 A; A/B/C/D=126-490.
DR   PDB; 6EIL; X-ray; 2.46 A; A/B/C/D=126-490.
DR   PDB; 6EIP; X-ray; 2.56 A; A/B/C/D=126-490.
DR   PDB; 6EIQ; X-ray; 2.30 A; A/B/C/D=126-490.
DR   PDB; 6EIR; X-ray; 2.40 A; A/B/C/D=126-490.
DR   PDB; 6EIS; X-ray; 2.36 A; A/B/C/D=126-490.
DR   PDB; 6EIV; X-ray; 2.68 A; A/B/C/D=126-490.
DR   PDB; 6EJ4; X-ray; 2.88 A; A/B/C/D=126-490.
DR   PDB; 6LN1; X-ray; 2.70 A; A/B=135-480.
DR   PDB; 6QU2; X-ray; 2.90 A; A/B/C/D=127-485.
DR   PDB; 6S11; X-ray; 2.44 A; A/B=127-485.
DR   PDB; 6S14; X-ray; 1.05 A; A=127-485.
DR   PDB; 6S17; X-ray; 1.10 A; A=127-485.
DR   PDB; 6S1B; X-ray; 1.30 A; A=127-485.
DR   PDB; 6S1H; X-ray; 1.05 A; A=127-485.
DR   PDB; 6S1I; X-ray; 2.38 A; A/B/C/D=127-485.
DR   PDB; 6S1J; X-ray; 1.41 A; A=127-485.
DR   PDB; 6T6A; X-ray; 2.80 A; A/B/C/D=127-485.
DR   PDB; 6UIP; X-ray; 3.70 A; A/B/C=127-485.
DR   PDB; 6UWY; X-ray; 2.95 A; A/B/C/D=127-485.
DR   PDB; 6YF8; X-ray; 3.20 A; A/B/C/D=126-490.
DR   PDB; 7A4O; X-ray; 1.90 A; A/B=127-485.
DR   PDB; 7A4R; X-ray; 1.80 A; A/B=148-479.
DR   PDB; 7A4S; X-ray; 3.10 A; A=148-485.
DR   PDB; 7A4W; X-ray; 2.70 A; A/B=127-485.
DR   PDB; 7A4Z; X-ray; 1.90 A; A=148-485.
DR   PDB; 7A51; X-ray; 1.90 A; A=148-485.
DR   PDB; 7A52; X-ray; 2.10 A; A/B=148-479.
DR   PDB; 7A53; X-ray; 2.20 A; A/B=148-485.
DR   PDB; 7A55; X-ray; 2.20 A; A/B=127-485.
DR   PDB; 7A5B; X-ray; 2.60 A; A/B=127-485.
DR   PDB; 7A5D; X-ray; 1.80 A; A=148-485.
DR   PDB; 7A5L; X-ray; 2.10 A; A=148-485.
DR   PDB; 7A5N; X-ray; 2.30 A; A/B=148-485.
DR   PDB; 7AJ2; X-ray; 2.10 A; A=148-485.
DR   PDB; 7AJ4; X-ray; 2.00 A; A=148-485.
DR   PDB; 7AJ5; X-ray; 2.00 A; A=148-485.
DR   PDB; 7AJ7; X-ray; 2.90 A; A=148-485.
DR   PDB; 7AJ8; X-ray; 2.00 A; A=148-485.
DR   PDB; 7AJA; X-ray; 2.20 A; A=148-485.
DR   PDB; 7AJM; X-ray; 2.40 A; A/B=148-479.
DR   PDB; 7AJS; X-ray; 2.15 A; A/B=148-479.
DR   PDB; 7AJV; X-ray; 2.10 A; A/B=148-485.
DR   PDB; 7AJW; X-ray; 2.80 A; A=148-485.
DR   PDB; 7AJY; X-ray; 2.20 A; A/B=148-485.
DR   PDB; 7AK2; X-ray; 2.10 A; A/B=148-485.
DR   PDB; 7AKA; X-ray; 1.90 A; A/B=148-485.
DR   PDB; 7AKB; X-ray; 2.80 A; A/B=148-485.
DR   PDB; 7AKE; X-ray; 2.30 A; A/B=148-485.
DR   PDB; 7AKL; X-ray; 2.00 A; A=148-485.
DR   PDB; 7FHS; X-ray; 2.42 A; A/B/C/D=127-485.
DR   PDB; 7FHT; X-ray; 2.68 A; A/B/C/D=127-485.
DR   PDB; 7O7K; X-ray; 1.82 A; A/B=127-485.
DR   PDB; 7OY6; X-ray; 2.38 A; C=127-485.
DR   PDBsum; 2VX3; -.
DR   PDBsum; 2WO6; -.
DR   PDBsum; 3ANQ; -.
DR   PDBsum; 3ANR; -.
DR   PDBsum; 4AZE; -.
DR   PDBsum; 4MQ1; -.
DR   PDBsum; 4MQ2; -.
DR   PDBsum; 4NCT; -.
DR   PDBsum; 4YLJ; -.
DR   PDBsum; 4YLK; -.
DR   PDBsum; 4YLL; -.
DR   PDBsum; 4YU2; -.
DR   PDBsum; 5A3X; -.
DR   PDBsum; 5A4E; -.
DR   PDBsum; 5A4L; -.
DR   PDBsum; 5A4Q; -.
DR   PDBsum; 5A4T; -.
DR   PDBsum; 5A54; -.
DR   PDBsum; 5AIK; -.
DR   PDBsum; 6A1F; -.
DR   PDBsum; 6A1G; -.
DR   PDBsum; 6EIF; -.
DR   PDBsum; 6EIJ; -.
DR   PDBsum; 6EIL; -.
DR   PDBsum; 6EIP; -.
DR   PDBsum; 6EIQ; -.
DR   PDBsum; 6EIR; -.
DR   PDBsum; 6EIS; -.
DR   PDBsum; 6EIV; -.
DR   PDBsum; 6EJ4; -.
DR   PDBsum; 6LN1; -.
DR   PDBsum; 6QU2; -.
DR   PDBsum; 6S11; -.
DR   PDBsum; 6S14; -.
DR   PDBsum; 6S17; -.
DR   PDBsum; 6S1B; -.
DR   PDBsum; 6S1H; -.
DR   PDBsum; 6S1I; -.
DR   PDBsum; 6S1J; -.
DR   PDBsum; 6T6A; -.
DR   PDBsum; 6UIP; -.
DR   PDBsum; 6UWY; -.
DR   PDBsum; 6YF8; -.
DR   PDBsum; 7A4O; -.
DR   PDBsum; 7A4R; -.
DR   PDBsum; 7A4S; -.
DR   PDBsum; 7A4W; -.
DR   PDBsum; 7A4Z; -.
DR   PDBsum; 7A51; -.
DR   PDBsum; 7A52; -.
DR   PDBsum; 7A53; -.
DR   PDBsum; 7A55; -.
DR   PDBsum; 7A5B; -.
DR   PDBsum; 7A5D; -.
DR   PDBsum; 7A5L; -.
DR   PDBsum; 7A5N; -.
DR   PDBsum; 7AJ2; -.
DR   PDBsum; 7AJ4; -.
DR   PDBsum; 7AJ5; -.
DR   PDBsum; 7AJ7; -.
DR   PDBsum; 7AJ8; -.
DR   PDBsum; 7AJA; -.
DR   PDBsum; 7AJM; -.
DR   PDBsum; 7AJS; -.
DR   PDBsum; 7AJV; -.
DR   PDBsum; 7AJW; -.
DR   PDBsum; 7AJY; -.
DR   PDBsum; 7AK2; -.
DR   PDBsum; 7AKA; -.
DR   PDBsum; 7AKB; -.
DR   PDBsum; 7AKE; -.
DR   PDBsum; 7AKL; -.
DR   PDBsum; 7FHS; -.
DR   PDBsum; 7FHT; -.
DR   PDBsum; 7O7K; -.
DR   PDBsum; 7OY6; -.
DR   AlphaFoldDB; Q13627; -.
DR   SMR; Q13627; -.
DR   BioGRID; 108192; 436.
DR   DIP; DIP-39750N; -.
DR   ELM; Q13627; -.
DR   IntAct; Q13627; 60.
DR   MINT; Q13627; -.
DR   STRING; 9606.ENSP00000381932; -.
DR   BindingDB; Q13627; -.
DR   ChEMBL; CHEMBL2292; -.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugBank; DB07608; N-(5-{[(2S)-4-amino-2-(3-chlorophenyl)butanoyl]amino}-1H-indazol-3-yl)benzamide.
DR   DrugCentral; Q13627; -.
DR   GuidetoPHARMACOLOGY; 2009; -.
DR   GlyGen; Q13627; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; Q13627; -.
DR   PhosphoSitePlus; Q13627; -.
DR   BioMuta; DYRK1A; -.
DR   DMDM; 3219996; -.
DR   EPD; Q13627; -.
DR   jPOST; Q13627; -.
DR   MassIVE; Q13627; -.
DR   MaxQB; Q13627; -.
DR   PaxDb; Q13627; -.
DR   PeptideAtlas; Q13627; -.
DR   PRIDE; Q13627; -.
DR   ProteomicsDB; 59619; -. [Q13627-1]
DR   ProteomicsDB; 59620; -. [Q13627-2]
DR   ProteomicsDB; 59621; -. [Q13627-3]
DR   ProteomicsDB; 59622; -. [Q13627-4]
DR   ProteomicsDB; 59623; -. [Q13627-5]
DR   Antibodypedia; 8587; 423 antibodies from 38 providers.
DR   DNASU; 1859; -.
DR   Ensembl; ENST00000338785.8; ENSP00000342690.3; ENSG00000157540.22. [Q13627-5]
DR   Ensembl; ENST00000398956.2; ENSP00000381929.2; ENSG00000157540.22. [Q13627-3]
DR   Ensembl; ENST00000398960.7; ENSP00000381932.2; ENSG00000157540.22. [Q13627-1]
DR   Ensembl; ENST00000643624.1; ENSP00000493627.1; ENSG00000157540.22. [Q13627-2]
DR   Ensembl; ENST00000644942.1; ENSP00000494544.1; ENSG00000157540.22. [Q13627-1]
DR   Ensembl; ENST00000645424.1; ENSP00000494897.1; ENSG00000157540.22. [Q13627-4]
DR   Ensembl; ENST00000646548.1; ENSP00000495908.1; ENSG00000157540.22. [Q13627-2]
DR   Ensembl; ENST00000647188.2; ENSP00000494572.1; ENSG00000157540.22. [Q13627-2]
DR   Ensembl; ENST00000647425.1; ENSP00000496748.1; ENSG00000157540.22. [Q13627-2]
DR   GeneID; 1859; -.
DR   KEGG; hsa:1859; -.
DR   MANE-Select; ENST00000647188.2; ENSP00000494572.1; NM_001347721.2; NP_001334650.1. [Q13627-2]
DR   UCSC; uc002ywi.4; human. [Q13627-1]
DR   CTD; 1859; -.
DR   DisGeNET; 1859; -.
DR   GeneCards; DYRK1A; -.
DR   GeneReviews; DYRK1A; -.
DR   HGNC; HGNC:3091; DYRK1A.
DR   HPA; ENSG00000157540; Low tissue specificity.
DR   MalaCards; DYRK1A; -.
DR   MIM; 600855; gene.
DR   MIM; 614104; phenotype.
DR   neXtProt; NX_Q13627; -.
DR   OpenTargets; ENSG00000157540; -.
DR   Orphanet; 268261; DYRK1A-related intellectual disability syndrome due to 21q22.13q22.2 microdeletion.
DR   Orphanet; 464311; Intellectual disability syndrome due to a DYRK1A point mutation.
DR   PharmGKB; PA27545; -.
DR   VEuPathDB; HostDB:ENSG00000157540; -.
DR   eggNOG; KOG0667; Eukaryota.
DR   GeneTree; ENSGT00940000157408; -.
DR   HOGENOM; CLU_000288_5_6_1; -.
DR   InParanoid; Q13627; -.
DR   OMA; PPIGWTA; -.
DR   OrthoDB; 271572at2759; -.
DR   PhylomeDB; Q13627; -.
DR   TreeFam; TF314624; -.
DR   BRENDA; 2.7.12.1; 2681.
DR   PathwayCommons; Q13627; -.
DR   Reactome; R-HSA-1538133; G0 and Early G1.
DR   SignaLink; Q13627; -.
DR   SIGNOR; Q13627; -.
DR   BioGRID-ORCS; 1859; 113 hits in 1129 CRISPR screens.
DR   ChiTaRS; DYRK1A; human.
DR   EvolutionaryTrace; Q13627; -.
DR   GeneWiki; DYRK1A; -.
DR   GenomeRNAi; 1859; -.
DR   Pharos; Q13627; Tchem.
DR   PRO; PR:Q13627; -.
DR   Proteomes; UP000005640; Chromosome 21.
DR   RNAct; Q13627; protein.
DR   Bgee; ENSG00000157540; Expressed in amniotic fluid and 210 other tissues.
DR   ExpressionAtlas; Q13627; baseline and differential.
DR   Genevisible; Q13627; HS.
DR   GO; GO:0030424; C:axon; ISS:ARUK-UCL.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005856; C:cytoskeleton; IEA:Ensembl.
DR   GO; GO:0030425; C:dendrite; ISS:ARUK-UCL.
DR   GO; GO:0016607; C:nuclear speck; ISS:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:1990904; C:ribonucleoprotein complex; IEA:Ensembl.
DR   GO; GO:0003779; F:actin binding; IPI:ARUK-UCL.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0008092; F:cytoskeletal protein binding; IPI:ARUK-UCL.
DR   GO; GO:0140857; F:histone kinase activity (H3-T45 specific); IDA:GO_Central.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; IDA:MGI.
DR   GO; GO:0004672; F:protein kinase activity; TAS:ProtInc.
DR   GO; GO:0043621; F:protein self-association; ISS:UniProtKB.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IGI:ARUK-UCL.
DR   GO; GO:0004712; F:protein serine/threonine/tyrosine kinase activity; IEA:UniProtKB-EC.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; ISS:UniProtKB.
DR   GO; GO:0008353; F:RNA polymerase II CTD heptapeptide repeat kinase activity; IDA:UniProtKB.
DR   GO; GO:0048156; F:tau protein binding; ISS:ARUK-UCL.
DR   GO; GO:0050321; F:tau-protein kinase activity; NAS:ARUK-UCL.
DR   GO; GO:0003713; F:transcription coactivator activity; IBA:GO_Central.
DR   GO; GO:0015631; F:tubulin binding; IPI:ARUK-UCL.
DR   GO; GO:0034205; P:amyloid-beta formation; IMP:ARUK-UCL.
DR   GO; GO:0007623; P:circadian rhythm; ISS:UniProtKB.
DR   GO; GO:0043518; P:negative regulation of DNA damage response, signal transduction by p53 class mediator; ISS:BHF-UCL.
DR   GO; GO:0090310; P:negative regulation of DNA methylation-dependent heterochromatin assembly; IDA:GO_Central.
DR   GO; GO:0031115; P:negative regulation of microtubule polymerization; ISS:ARUK-UCL.
DR   GO; GO:0048025; P:negative regulation of mRNA splicing, via spliceosome; IEA:Ensembl.
DR   GO; GO:0007399; P:nervous system development; TAS:ProtInc.
DR   GO; GO:0036289; P:peptidyl-serine autophosphorylation; TAS:ARUK-UCL.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IGI:ARUK-UCL.
DR   GO; GO:0018107; P:peptidyl-threonine phosphorylation; ISS:BHF-UCL.
DR   GO; GO:0038083; P:peptidyl-tyrosine autophosphorylation; IDA:ARUK-UCL.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:MGI.
DR   GO; GO:0045893; P:positive regulation of DNA-templated transcription; IBA:GO_Central.
DR   GO; GO:0090312; P:positive regulation of protein deacetylation; ISS:BHF-UCL.
DR   GO; GO:0033120; P:positive regulation of RNA splicing; IDA:ARUK-UCL.
DR   GO; GO:0046777; P:protein autophosphorylation; ISS:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; ISS:UniProtKB.
DR   CDD; cd14226; PKc_DYRK1; 1.
DR   InterPro; IPR028318; DYRK1A/B_MNB.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR044131; PKc_DYR1A/1B.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   PANTHER; PTHR24058:SF121; PTHR24058:SF121; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Host-virus interaction;
KW   Intellectual disability; Kinase; Nucleotide-binding; Nucleus;
KW   Phosphoprotein; Reference proteome; Serine/threonine-protein kinase;
KW   Transcription; Transcription regulation; Transferase;
KW   Tyrosine-protein kinase.
FT   CHAIN           1..763
FT                   /note="Dual specificity tyrosine-phosphorylation-regulated
FT                   kinase 1A"
FT                   /id="PRO_0000085931"
FT   DOMAIN          159..479
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          32..57
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          115..136
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          408..442
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          485..540
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          595..625
FT                   /note="Histidine-rich domain (HRD)"
FT                   /evidence="ECO:0000269|PubMed:29849146"
FT   REGION          596..679
FT                   /note="Disordered"
FT                   /evidence="ECO:0000269|PubMed:29849146"
FT   REGION          744..763
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           117..134
FT                   /note="Bipartite nuclear localization signal"
FT                   /evidence="ECO:0000255"
FT   COMPBIAS        34..57
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        485..528
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        601..624
FT                   /note="Basic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        627..679
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        287
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000305|PubMed:23665168"
FT   BINDING         165..173
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000305"
FT   BINDING         188
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000305"
FT   BINDING         238..241
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000305"
FT   MOD_RES         14
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         111
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:23665168"
FT   MOD_RES         140
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:23665168"
FT   MOD_RES         145
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         159
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:23665168"
FT   MOD_RES         177
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:23665168"
FT   MOD_RES         219
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000250|UniProtKB:Q63470"
FT   MOD_RES         310
FT                   /note="Phosphoserine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:23665168"
FT   MOD_RES         319
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:23665168"
FT   MOD_RES         321
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:23665168"
FT   MOD_RES         402
FT                   /note="Phosphothreonine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:23665168"
FT   MOD_RES         449
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:23665168"
FT   MOD_RES         529
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         538
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q61214"
FT   MOD_RES         748
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976"
FT   MOD_RES         758
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976"
FT   VAR_SEQ         70..78
FT                   /note="Missing (in isoform 1)"
FT                   /evidence="ECO:0000303|PubMed:8769099,
FT                   ECO:0000303|PubMed:9037601"
FT                   /id="VSP_004917"
FT   VAR_SEQ         516..529
FT                   /note="GGSSGTSNSGRARS -> GASAISCSSWLVRH (in isoform 2)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_004918"
FT   VAR_SEQ         516..525
FT                   /note="GGSSGTSNSG -> GGAALDARCL (in isoform 3)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_004920"
FT   VAR_SEQ         526..763
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_004921"
FT   VAR_SEQ         530..763
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_004919"
FT   VAR_SEQ         559..584
FT                   /note="RQQFPAPLGWSGTEAPTQVTVETHPV -> SSHVVHLLVSPAILRWSSTGCQ
FT                   VPLE (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:10329007"
FT                   /id="VSP_004922"
FT   VAR_SEQ         585..763
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:10329007"
FT                   /id="VSP_004923"
FT   VARIANT         415
FT                   /note="Y -> F"
FT                   /evidence="ECO:0000269|PubMed:10329007"
FT                   /id="VAR_009395"
FT   VARIANT         679
FT                   /note="A -> P (in dbSNP:rs55720916)"
FT                   /evidence="ECO:0000269|PubMed:17344846,
FT                   ECO:0000269|PubMed:8975710"
FT                   /id="VAR_040453"
FT   VARIANT         681
FT                   /note="Q -> H"
FT                   /evidence="ECO:0000269|PubMed:10329007"
FT                   /id="VAR_009396"
FT   MUTAGEN         188
FT                   /note="K->R: Abolished protein kinase activity."
FT                   /evidence="ECO:0000269|PubMed:23665168,
FT                   ECO:0000269|PubMed:25620562"
FT   MUTAGEN         321
FT                   /note="Y->F: Mildly reduces kinase activity. Does not
FT                   abolish autophosphorylation on tyrosine residues."
FT                   /evidence="ECO:0000269|PubMed:23665168"
FT   CONFLICT        32
FT                   /note="G -> A (in Ref. 1; AAC50939)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        47
FT                   /note="N -> S (in Ref. 1; AAC50939)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        57
FT                   /note="S -> P (in Ref. 1; AAC50939)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        123
FT                   /note="Q -> R (in Ref. 1; AAC50939)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        266
FT                   /note="A -> V (in Ref. 6; CAA05059)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        357
FT                   /note="G -> R (in Ref. 6; CAA05059)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        397
FT                   /note="K -> N (in Ref. 1; AAC50939)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        592
FT                   /note="A -> G (in Ref. 1; AAC50939)"
FT                   /evidence="ECO:0000305"
FT   HELIX           137..139
FT                   /evidence="ECO:0007829|PDB:6S14"
FT   TURN            156..158
FT                   /evidence="ECO:0007829|PDB:6S14"
FT   STRAND          159..168
FT                   /evidence="ECO:0007829|PDB:6S14"
FT   STRAND          171..178
FT                   /evidence="ECO:0007829|PDB:6S14"
FT   TURN            179..182
FT                   /evidence="ECO:0007829|PDB:6S14"
FT   STRAND          183..190
FT                   /evidence="ECO:0007829|PDB:6S14"
FT   HELIX           194..212
FT                   /evidence="ECO:0007829|PDB:6S14"
FT   STRAND          215..217
FT                   /evidence="ECO:0007829|PDB:7AKL"
FT   STRAND          219..221
FT                   /evidence="ECO:0007829|PDB:6S1H"
FT   STRAND          224..230
FT                   /evidence="ECO:0007829|PDB:6S14"
FT   STRAND          233..238
FT                   /evidence="ECO:0007829|PDB:6S14"
FT   HELIX           245..251
FT                   /evidence="ECO:0007829|PDB:6S14"
FT   TURN            252..254
FT                   /evidence="ECO:0007829|PDB:6S14"
FT   HELIX           259..276
FT                   /evidence="ECO:0007829|PDB:6S14"
FT   TURN            279..281
FT                   /evidence="ECO:0007829|PDB:6S14"
FT   HELIX           290..292
FT                   /evidence="ECO:0007829|PDB:6S14"
FT   STRAND          293..297
FT                   /evidence="ECO:0007829|PDB:6S14"
FT   TURN            299..301
FT                   /evidence="ECO:0007829|PDB:7O7K"
FT   STRAND          303..305
FT                   /evidence="ECO:0007829|PDB:6S14"
FT   HELIX           308..310
FT                   /evidence="ECO:0007829|PDB:7OY6"
FT   HELIX           314..316
FT                   /evidence="ECO:0007829|PDB:6S1H"
FT   HELIX           325..327
FT                   /evidence="ECO:0007829|PDB:6S14"
FT   HELIX           330..333
FT                   /evidence="ECO:0007829|PDB:6S14"
FT   HELIX           341..356
FT                   /evidence="ECO:0007829|PDB:6S14"
FT   HELIX           366..377
FT                   /evidence="ECO:0007829|PDB:6S14"
FT   HELIX           382..385
FT                   /evidence="ECO:0007829|PDB:6S14"
FT   HELIX           391..394
FT                   /evidence="ECO:0007829|PDB:6S14"
FT   STRAND          395..397
FT                   /evidence="ECO:0007829|PDB:6S14"
FT   TURN            399..401
FT                   /evidence="ECO:0007829|PDB:7A5D"
FT   STRAND          403..405
FT                   /evidence="ECO:0007829|PDB:6S14"
FT   HELIX           409..411
FT                   /evidence="ECO:0007829|PDB:6S1I"
FT   HELIX           423..426
FT                   /evidence="ECO:0007829|PDB:6S14"
FT   TURN            427..432
FT                   /evidence="ECO:0007829|PDB:6S14"
FT   HELIX           434..436
FT                   /evidence="ECO:0007829|PDB:6S14"
FT   TURN            437..440
FT                   /evidence="ECO:0007829|PDB:6S14"
FT   STRAND          441..443
FT                   /evidence="ECO:0007829|PDB:7A4R"
FT   HELIX           446..459
FT                   /evidence="ECO:0007829|PDB:6S14"
FT   TURN            464..466
FT                   /evidence="ECO:0007829|PDB:6S14"
FT   HELIX           470..475
FT                   /evidence="ECO:0007829|PDB:6S14"
FT   HELIX           477..479
FT                   /evidence="ECO:0007829|PDB:4YLK"
SQ   SEQUENCE   763 AA;  85584 MW;  7C3A52A3CBB04FB5 CRC64;
     MHTGGETSAC KPSSVRLAPS FSFHAAGLQM AGQMPHSHQY SDRRQPNISD QQVSALSYSD
     QIQQPLTNQV MPDIVMLQRR MPQTFRDPAT APLRKLSVDL IKTYKHINEV YYAKKKRRHQ
     QGQGDDSSHK KERKVYNDGY DDDNYDYIVK NGEKWMDRYE IDSLIGKGSF GQVVKAYDRV
     EQEWVAIKII KNKKAFLNQA QIEVRLLELM NKHDTEMKYY IVHLKRHFMF RNHLCLVFEM
     LSYNLYDLLR NTNFRGVSLN LTRKFAQQMC TALLFLATPE LSIIHCDLKP ENILLCNPKR
     SAIKIVDFGS SCQLGQRIYQ YIQSRFYRSP EVLLGMPYDL AIDMWSLGCI LVEMHTGEPL
     FSGANEVDQM NKIVEVLGIP PAHILDQAPK ARKFFEKLPD GTWNLKKTKD GKREYKPPGT
     RKLHNILGVE TGGPGGRRAG ESGHTVADYL KFKDLILRML DYDPKTRIQP YYALQHSFFK
     KTADEGTNTS NSVSTSPAME QSQSSGTTSS TSSSSGGSSG TSNSGRARSD PTHQHRHSGG
     HFTAAVQAMD CETHSPQVRQ QFPAPLGWSG TEAPTQVTVE THPVQETTFH VAPQQNALHH
     HHGNSSHHHH HHHHHHHHHG QQALGNRTRP RVYNSPTNSS STQDSMEVGH SHHSMTSLSS
     STTSSSTSSS STGNQGNQAY QNRPVAANTL DFGQNGAMDV NLTVYSNPRQ ETGIAGHPTY
     QFSANTGPAH YMTEGHLTMR QGADREESPM TGVCVQQSPV ASS
//
